“Achieving Clinical Remission in Asthma with Mepolizumab: A Subanalysis on Vitamin D as a Predictor of Response”

Mepolizumab, an anti-IL-5 monoclonal antibody, has shown promise in reducing exacerbations and steroid dependency in severe eosinophilic asthma. This study aims to evaluate the effectiveness of mepolizumab in achieving clinical remission in asthma over 12 months and explore Vitamin D levels as a predictor of response.